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Nicaraven, a hydroxyl radical-specific scavenger has been demonstrated to attenuate 
radiation injury in hematopoietic stem cells with 5 Gy γ-ray exposures. We explored the 
effect and related mechanisms of nicaraven for protecting radiation injury induced by 
sequential exposures to a relatively lower dose γ-ray. C57BL/6 mice were given nicaraven 
or placebo within 30 minutes before exposure to 50 mGy γ-ray daily for 30 days in 
sequences (cumulative dose of 1.5 Gy). Mice were victimized 24 hours after the last 
radiation exposure, and the number, function and oxidative stress of hematopoietic stem 
cells were quantitatively estimated. We also compared the gene expression in these 
purified stem cells from mice received nicaraven and placebo treatment. Nicaraven 
increased the number of c-kit+ stem/progenitor cells in bone marrow and peripheral blood, 
with a recovery rate around 60~90% of age-matched non-irradiated healthy mice. The 
potency of colony forming from hematopoietic stem/progenitor cells as indicator of 
function was completely protected with nicaraven treatment. Furthermore, nicaraven 
treatment changed the expression of many genes associated to DNA repair, inflammatory 
response, and immunomodulation in c-kit+ stem/progenitor cells. Nicaraven effectively 
protected against damages of hematopoietic stem/progenitor cells induced by sequential 







Acute exposure to ionizing radiation at a dose range of 0.7 to 4 Gy is well defined 
to develop symptoms associated with hematopoietic and immune damages [1]. It has also 
reported the increased incidence of cancer risk in nuclear workers who classically exposed 
to low doses of extraordinary rates [2]. Furthermore, medical doctors and technicians have 
been shown high incidence of chromosomal disruptions and hematopoietic malignancies 
even if with exposure to less than 50 mGy [3-5]. Although many chemical and biological 
compounds were widely tested for protecting against radiation injury [6,7], there is only 
amifostine, a scavenger of reactive oxygen species (ROS) had been approved clinically as 
a  cytoprotective adjuvant to alleviate the side effects for patients who get radiotherapy [8]. 
Unfortunately, the administration of amifostine is limited due to its accumulative toxicity 
and side effects, including nausea, vomiting, hypotension, and allergic reactions [9]. 
Therefore, it is highly required to develop new agents of less or no toxicity for protecting 
against the potential health threats from natural, incidental, and occupational exposures to 
relative low dose radiations. 
Nicaraven (1,2-bis (nicotinamido)-propane),  synthesized chemical compound 
known as a hydroxyl radical-specific scavenger [10], had previously been found to amend 
the survival of mice exposed to a lethal dose of γ-ray [11], and to protect against radiation-
induced cell death [12,13]. We have recently demonstrated that the administration of 
nicaraven to mice soon after the exposure to a high dose of γ-ray attenuates the radiation-
induced injury of hematopoietic stem/progenitor cells, via reduction of DNA damage of 
cells and inhibition of inflammation [14]. Taking the safety profile of nicaraven and the 
potential long-term healthy risk of occupational radiation exposures in consideration [2, 
15], it will be so interesting to confirm the prophylactic effect of nicaraven on radiation-
induced injury, especially on these immature stem/progenitor cells after the exposure to 
relatively lower dose. 





dose of 1.5 Gy), we investigated the prophylactic effect of administration of nicaraven 
against radiation-induced injury in hematopoietic stem/progenitor cells, and further to 
understand the relevant mechanisms. 
 
Materials and Methods 
Animals 
We used 8- to 12-week-old male C57BL/6 mice (SLC, Japan) for the present study. 
All experiments were approved by the Institutional Animal Care and Use Committee of 
Nagasaki University (No. 1108120943), and the animal procedures were performed in 
accordance with institutional and national guidelines.  
 
Radiation exposure and nicaraven administration 
Whole-body radiation was done by exposing the mice to γ-rays with a 137Cs source 
in PS-3100SB γ-ray irradiation system (Pony Industry Co., Ltd. Osaka, Japan) [16]. To 
explore the effect and relevant mechanisms of nicaraven for protecting radiation-induced 
injury in hematopoietic stem/progenitor cells, mice were daily exposed to 50 mGy γ-rays 
for 30 days in sequences (cumulative dose of 1.5 Gy). Intraperitoneal injection with 100 
mg/kg nicaraven [14] (Nicaraven group, n=6) or saline only (Placebo group, n=6) was 
done within 30 minutes before each exposure. Mice were victimized 24 hours after the last 
exposure, and samples of blood and bone marrow cells were collected for the subsequent 
experiments. 
 
Measurements of stem cells in the peripheral blood and bone marrow 
        Samples of heparinized peripheral blood were collected, and the number of 
mononuclear cells in the blood was counted using a NucleoCounter (Chemotetec A/S, 
Denmark). To measure the c-kit-positive (c-kit+) stem/progenitor cells, we isolated the 





labeled with a PE-conjugated anti-mouse CD117 (c-kit) antibody (eBioscience) for 30 
minutes. Respective isotype control was used as a negative control. After washing, 
quantitative flow cytometry was performed using a FACSCalibur (Becton Dickinson) [17]. 
We analyzed the acquired data using Cell Quest software (Becton Dickinson). 
           Bone marrow cells were collected from the femur and tibia, and the mononuclear 
cells were isolated by density gradient centrifugation. The c-kit+ cells in the collected bone 
marrow mononuclear cells were measured as described above. 
 
Colony-forming assay 
            To evaluate the function of stem/progenitor cells from peripheral blood and bone 
marrow, a colony-forming assay was performed by using mouse methylcellulose complete 
medium, according to the manufacturer’s instructions (R&D System). Briefly, 1x105 
peripheral nucleated cells or 3x104 bone marrow mononuclear cells were mixed well with 
1 ml of medium, plated in 3-cm culture dishes, and then incubated at 37°C in a 5% CO2 
incubator. The formation of colonies was observed under a microscopy, and the number of 
colonies was counted after 9 days (for bone marrow mononuclear cells) or 12 days (for 
peripheral blood nucleated cells) of incubation. The average number of colonies from 
duplicated assays was used for the statistical analyses. 
 
Purification of c-kit+ stem/progenitor cells 
The c-kit+ stem/progenitor cells were purified by using the magnetic cell sorting 
system (autoMACS, Miltenyi Biotec, Auburn, CA). Briefly, freshly collected bone 
marrow mononuclear cells were incubated with microbeads-conjugated anti-mouse 
CD117 (c-kit) antibody (Miltenyi Biotec) for 30 minutes. After washing, c-kit+ cells were 
separated by passing a MACS column. The purity of the c-kit+ cells collected by the 






Detection of intracellular ROS 
To elucidate the relevant mechanism, we measured the intracellular ROS level 
based on the oxidation of 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein 
diacetate, acetyl ester (CM-H2DCFDA, Molecular Probes Inc.) to form the fluorescent 
compound 2',7'-dichlorofluorescein (DCF), as described previously [16,18]. Briefly, 
freshly separated c-kit+ cells and c-kit-negative cells were seeded in 96-well culture plates 
(1x104 cells/100 μl/well) and incubated at 37°C in a 5% CO2 incubator for 24 hrs. Cells 
were then loaded with 10 µM CM-H2DCFDA at 37°C for 30 minutes. After the cells were 
washed, the fluorescence intensities of the wells were measured using the (ARVO X3 
plate reader, Perkin Elmer).  
 
Mouse Molecular Toxicology Pathway Finder RT2 Profiler PCR array 
To compare the gene expression, RNA was isolated from pelleted c-kit+ cells by 
using RNeasy Mini Kit and RNAse free DNase (Qiagen, Hilden, Germany). The 
concentration of RNA was determined using Nano Drop (Thermo Scientific, Wilmington, 
DE, USA), and 1 mg of RNA was used to generate cDNA using RT2 First Strand Kit 
(SABiosciences, a Qiagen Company). Mouse Molecular Toxicology Pathway Finder RT2 
Profiler PCR array was done according to the manufacturer’s instructions 
(SABiosciences). This PCR array profiled the expression of 370 genes representative of 
the 13 biological pathways involved in response to toxic drugs (Supporting Table 1) and 
exhibited good reproducibility of data [19]. The fold change of expression was calculated 
using SABiosciences’ web-based data analysis program. Results represent the mean of 
four independent samples from nicaraven and placebo. 
 
Statistical analyses 
Data were represented as means ± SD. The statistical significance was determined 





Chicago, IL). The p value less than 0.05 were accepted as significant. 
 
Results 
Nicaraven mitigated the radiation-induced reduction of peripheral blood nucleated cells 
and c-kit+ stem/progenitor cells 
Compared with the placebo treatment, the administration of nicaraven increased 
the number of nucleated cells in the peripheral blood (6.3±1.2 x105 vs. 4.1±0.4 x105, 
p<0.001; Fig 1A), but it was still measured as only 60% of the level of non-irradiated 
healthy mice (11.0±1.3 x105, p<0.01; Fig 1A). The exposure to 50 mGy for 30 days also  
decreased the percentage of c-kit+ cells in the peripheral blood to around 50% of the level 
of non-irradiated healthy mice (p<0.05, Fig 1B). However, the administration of nicaraven 
increased the percentage of c-kit+ cells in the peripheral blood (0.053±0.02% vs. 
0.024±0.01% in Placebo, p<0.05; Fig 1B), which resulted to keep the c-kit+ cells at a 
comparable level of non-irradiated healthy mice (0.058±0.02%, p=0.7; Fig 1B).  
 
Nicaraven alleviated the radiation-induced reduction of bone marrow mononuclear 
cells and c-kit+ stem/progenitor cells 
Compared with the placebo treatment, the administration of nicaraven increased 
the number of mononuclear cells (69.5±5.0 x106 vs. 55.2±9.0 x106, p<0.05; Fig 2A), and 
even higher than the non-irradiated healthy mice (63.8±3.2 x106 vs. 69.5±5.0 x106, 
p<0.05; Fig 2A). However, the percentage of c-kit+ cells in the nicaraven-treated mice 
were still measured as almost 55% of the non-irradiated healthy mice (1.9±0.1% vs. 
3.7±0.6%, p<0.001, Fig 2B), although it was higher than that of in placebo treatment 
(1.4±0.2%, p<0.01, Fig 2B).  
 
Nicaraven enhanced the function of hematopoietic stem/progenitor cells 





colony-forming assay in vitro. The formation of colonies was also clearly detectable 
within 12 days from peripheral blood nucleated cells. By quantitatively counting, we 
found that the total number of colonies formed from peripheral blood nucleated cells was 
higher in the Nicaraven group than Placebo group (8.0±2.1 vs. 5.0±1.0, p<0.05; Fig 3A). 
The potency of colonies formation from peripheral blood nucleated cells of the nicaraven-
treated mice was kept almost the same as that of the non-irradiated healthy mice (7.3±1.2, 
p=0.52; Fig 3A) 
The formation of different types of colonies was obviously observed from bone 
marrow mononuclear cells after 9 days of culture. Although we did not measure the 
overall size, colonies was bigger in size in the Nicaraven group than of Placebo group. 
Also, the total number of colonies resulting from bone marrow mononuclear cells was 
higher in the Nicaraven group than of Placebo group (75.8±2.7 vs. 52.2±6.0, p<0.001; Fig 
3B). However, the size and number of colonies resulting from the nicaraven-treated mice 
were quite similar as that of the non-irradiated healthy mice (81.8±6.6, p=0.08; Fig 3B).  
 
Nicaraven diminished slightly the levels of intracellular ROS 
As nicaraven is well recognized as a hydroxyl radical-specific scavenger, we 
measured the level of intracellular ROS in purified c-kit+ cells. Unexpectedly, the 
intracellular ROS levels in both of c-kit+ stem/progenitor cells and c-kit-negative matured 
bone marrow mononuclear cells were measured very similar among groups, although the 
ROS level was slightly decreased by nicaraven treatment (Fig 4). 
 
Complex mechanisms involved in the protective effect of nicaraven to radiation injury 
          We used a Mouse Molecular Toxicology Pathway Finder RT2 Profiler PCR array to 
screen the gene expression changes. Among the total of 370 genes included in the array, 
208 genes were detected to be up- or down-regulated over two-fold by the nicaraven 





were listed up in tables (Table 1 and 2). We noticed that the most of top 20 genes with up- 
or down-regulation by nicaraven treatment were functionally associated with DNA 
damage repair (Brca2, Prkdc and Ercc2), ER stress gene (Ube2g2), cell apoptosis (Bcl2l1, 
Bid and Bad), inflammatory response (TNF, IL1a), immunomodulation (C3, CD36), and 
beta oxidation (ACOX1), suggested complex mechanisms were involved in the protective 
effect of nicaraven to radiation injury. 
 
Discussion 
In this study, we have demonstrated that the administration of nicaraven can 
effectively mitigate the damage of hematopoietic stem/progenitor cells in mice exposed to 
successive relatively low dose of γ-ray (daily 50 mGy for 30 days). We have further found 
that the protective effect of nicaraven against radiation-induced injury to hematopoietic 
stem/progenitor cells likely associated with complex mechanisms included the inhibition 
of inflammation, immunomodulation and enhancement of DNA repair, rather than a 
simple radical scavenger reducing ROS. 
A high dose ionizing radiation can directly lead to DNA double-strand break to kill 
the cells. It has also generally accepted that the exposure to even relative low dose of 
radiation may trigger the generation of ROS, which indirectly induce DNA damage and 
genomic instability [20]. Therefore, quickly scavenging the ROS by radical scavengers 
was considered as one of the effective approach for attenuating radiation-induced injury, 
especially that occupationally exposed to a relatively low dose radiation. Our study 
showed that nicaraven has a prophylactic effect on protecting c-kit+ hematopoietic 
stem/progenitor cells against radiation injury in mice exposed to a relatively low dose 
radiation, although the peripheral blood nucleated cells and the percentage of c-kit+ cells 
in bone marrow in mice received nicaraven treatment was not recovered to the levels of 
healthy mice.  





high dose radiation [14], surprisingly, the ROS level was only slightly decreased in these 
purified c-kit+ stem/progenitor cells from mice received nicaraven when compared to 
those received placebo treatment. This again suggests that nicaraven protection against 
radiation injury seems to be associated with other mechanism rather than as simple as a 
radical scavenger. To further understand the potential mechanisms of the protective effect 
of nicaraven against radiation injury, we purified c-kit+ stem/progenitor cells from mice 
received nicaraven or placebo treatment and then performed a PCR array analysis to 
compare the gene expression profile related to molecular toxicology pathways. Among the 
top 20 of up- and down-regulated genes, many genes are associated with DNA repair/ 
stress responses, inflammatory/ immunomodulation, cell apoptosis/ necrosis, and beta 
oxidation.  
Within these genes that associated with DNA damage repair (Supporting Fig 1), 
the most up-regulated gene of BRCA2  involved in homologous recombination repair 
pathway, which contributes to an error-free DNA repair that play an essential role in 
maintaining genome stability and tumor suppression [21,22]. Although, the most down-
regulated gene of OGGI1 has been demonstrated to remove damaged bases from the DNA, 
especially in repair of DNA damages induced by oxidative stress [23]. Although, 
nicaraven treatment slightly decreased the ROS level in these purified c-kit+  
stem/progenitor cells, it was exciting to investigate whether nicaraven decrease the DNA 
damage induced by oxidative stress , including a technical challenging to monitor the ROS 
level within the c-kit+ stem/progenitor cells in situ. Also, nicaraven up-regulated the 
expression of many genes associated with apoptosis (Supporting Fig 2), including 
BCL2L1, BID and BAD that required for radiation-induced apoptosis [24]. It is known that 
the defect of apoptosis cause genomic instability [25, 26]. Also, some DNA repair 
molecules induce apoptosis in response to DNA lesions, these genes associated with 
apoptosis and DNA repair work together to create a complex biological network for 





cell death, but also helps to commit these c-kit+ stem/progenitor cells with DNA damage 
into apoptosis. However, many necrotic genes were down-regulated by nicaraven 
treatment (Supporting Fig 3). 
Nicaraven treatment decreased the expressions of many genes associated with 
inflammatory response (Supporting Fig 4), including TNF and IL1a, in the top of the 
down-regulated genes. Furthermore, the decrease of immune function is highly observed 
after radiotherapy or occupationally exposures to even low level of ionizing radiation [28]. 
Interestingly, nicaraven up-regulated the expression of C3gene, it plays a central role in 
complement system and innate immunity [29]. Nicaraven treatment also up-regulated 
ACOX1, a gene involving the first step in beta oxidation process of fatty acid to produce 
ATP supporting cell withstand and survival [30,31], also playing roles in redox 
equilibrium [32]. Otherwise, nicaraven up-regulated other genes, such as Ube2g2 that 
involved in ER stress recovery and supporting cell survival under stress [33]. 
This study has some limitations. The first, although complex mechanisms, 
including DNA repair, inflammatory response, immunomodulation, and energy supply 
were likely involved in nicaraven for protection against radiation injury, further study will 
be needed to identify the precise mechanism. The second, we only measured the 
percentages of c-kit+ cells within bone marrow mononuclear cells and peripheral blood 
nucleated cells. However, it is still unclear whether the protective effect of nicaraven will 
be varied among different subtypes of stem/progenitor cells, such as the rare population of 
long-term hematopoietic stem cells (Lin-/Sca1+/c-Kit+, LSK cells). Otherwise, it is also 
important to compare the protective effect against radiation injury and the side effect of 
nicaraven with other drugs, including amifostine that is already approved for clinical 
application [8]. 
            In summary, we have confirmed that the prophylactic effect of nicaraven on 
protecting c-kit+ hematopoietic stem/progenitor cells against radiation injury in mice 





complex molecular mechanism was not completely understood, the excellent safety profile 
of nicaraven provides potential possibility as prophylactic treatment for protecting against 
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Table 1: The top 20 genes that up-regulated by nicaraven treatment. 
 




1 Brca2 Breast cancer 2 94.092 DNA Repair 
2 Ube2g2 Ubiquitin-conjugating enzyme E2G 2 84.800 ER stress 
3 C3 Complement component 3 79.672 Inflammatory 
and immunity 
4 Acox1 Acyl-Coenzyme A oxidase 1, palmitoyl 51.840 Beta Oxidation 
5 Mlx MAX-like protein X 47.373 Phospholipidosi
s 
6 Ercc2 
Excision repair cross-complementing 
rodent repair deficiency, 
complementation group 2 
32.809 DNA Repair 
7 Dnajc5 





8 Esr1 Estrogen receptor 1 (alpha) 23.039 Cholestasis 
9 Bad BCL2-associated agonist of cell death 22.565 Apoptosis 
10 Bid BH3 interacting domain death agonist 22.409 Apoptosis 
11 Nploc4 
Nuclear protein localization 4 homolog 
(S. cerevisiae) 18.844 ER stress 




13 Icam1 Intercellular adhesion molecule 1 13.232 Cholestasis 
14 Dnajc6 DnaJ (Hsp40) homolog, subfamily C, 
member 6 
12.346 Heat shock 
Response 




Protein kinase, DNA activated, catalytic 
polypeptide 12.009 DNA Repair 
17 Mttp Microsomal triglyceride transfer protein 11.600 Steatosis 
18 Bcl2l1 Bcl2-like 1 11.361 Apoptosis 
19 H2-Eb1 
Histocompatibility 2, class II antigen E 
beta 
9.822 Cholestasis 







Table 2: The top 20 genes that down-regulated by nicaraven treatment. 
 




1 TNF Tumor necrosis factor -137.568 
Inflammatory 
and immunity 
2 Cd86 CD86 antigen -63.734 Inflammatory 
and immunity 
3 Hsf2 Heat shock factor 2 -48.976 
Heat shock 
Response 
4 Cd19 CD19 antigen -48.976 
Inflammatory 
and immunity 
5 Cd80 CD80 antigen -47.968 Inflammatory 
and immunity 
6 Il1a Interleukin 1 alpha -41.184 
Inflammatory 
and immunity 
7 Hspa1l Heat shock protein 1-like -35.853 
Heat shock 
Response 
8 Dpysl4 Dihydropyrimidinase-like 4 -35.115 Necrosis 
9 Tff3 Trefoil factor 3, intestinal -29.733 Steatosis 
10 Hspb6 





11 Ogg1 8-oxoguanine DNA-glycosylase 1 -27.550 DNA Repair 
12 Cyp1a2 
Cytochrome P450, family 1, subfamily 




13 Fmo3 Flavin containing monooxygenase 3 -11.267 
Cytochrome 
P450s 
14 Lig4 Ligase IV, DNA, ATP-dependent -11.112 DNA Repair 
15 Jph3 Junctophilin 3 -9.945 Necrosis 
16 Aldh2 
Aldehyde dehydrogenase 2, 
mitochondrial 
-9.409 Steatosis 




ATPase, H+ transporting, lysosomal 
V1 subunit G2 
-7.749 Necrosis 
19 Sel1l 
Sel-1 suppressor of lin-12-like (C. 
elegans) -7.642 ER stress 
20 Ercc1 
Excision repair cross-complementing 
rodent repair deficiency, 
complementation group 1 







Fig 1. The number of nucleated cells and stem/progenitor cells in the peripheral blood of 
mice after radiation exposure and nicaraven treatment. The number of nucleated cells in 
the peripheral blood (A) was directly counted, and c-kit+ stem/progenitor cells (B) in the 
peripheral blood were measured in the fraction of the nucleated cells by flow cytometry. 
 
Fig 2. The number of mononuclear cells and stem/progenitor cells in the bone marrow of 
mice after radiation exposure and nicaraven treatment. The number of collected bone 
marrow mononuclear cells from each mouse was directly counted (A) and the c-kit+ 
stem/progenitor cells were measured by flow cytometry (B). 
 
Fig 3. Colony-forming assay. The formation of different types of colonies (>50 cells) was 
directly counted under microscopy. Data indicates the number of colonies formed from a 
total of 1x105 peripheral blood nucleated cells after 12 days of incubation (A), or 3x104 
bone marrow mononuclear cells after 9 days of incubation (B). 
 
Fig 4. Intracellular ROS in the bone marrow stem/progenitor cells in the bone marrow of 
mice after radiation exposure and nicaraven treatment. The intracellular ROS in the 
purified c-kit+ stem/progenitor cells (A) and c-kit-negative matured cells (B) were 
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